Acadia Pharmaceuticals layoffs, on the record
Every job cut, severance charge and restructuring Acadia Pharmaceuticals reported in its annual reports, 2023 to 2025, quoted from the filings.
Job cuts, severance and restructuring
Our summaryThe company recorded stock-based compensation expense tied to the departure of its former CEO, from accelerated equity award vesting and stock modifications under the former CEO's severance plan.
Word for word“In connection with the departure of the former CEO, in September 2024 the Company incurred approximately $ 10.7 million in stock-based compensation expense as a result of accelerated equity award vesting and stock modifications under the former CEO’s severance plan.” 10-K for 2024
Acadia Pharmaceuticals has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Acadia Pharmaceuticals’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.